Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes
Article Figures & Tables
Figures
- Figure 1—
Patient disposition. ITT, intent-to-treat population.
- Figure 2—
HbA1c from baseline in each treatment group (♦, placebo; ▪, nateglinide (120 mg); ▴, troglitazone (600 mg); •, nateglinide (120 mg) and troglitazone (600 mg).
Tables
- Table 1—
Baseline demographics and background characteristics of the randomized patient population
Variable Placebo Nateglinide 120 mg Troglitazone 600 mg Nateglinide 120 mg and Troglitazone 600 mg n 148 150 151 150 Sex (M/F %) 59/41 59/41 63/37 61/39 Race (%) Caucasian 74.3 79.3 80.1 82.7 Black 10.1 6.0 7.9 2.7 Asian/Oriental 0.7 1.3 1.3 1.3 Other 14.9 13.3 10.6 13.3 Mean age (years) 58 58 57 59 Range 32–83 34–83 33–86 31–82 Mean BMI (kg/m2) Range 20–38 21–38 19–37 21–45 Mean duration of diabetes (years) 4.7 5.1 4.2 4.2 Range 0.2–37.9 0.1–33.4 0–20.4 0.3–26.2 Mean HbA1c (%) 8.2 8.4 8.1 8.3 SD 1.2 1.1 1.0 1.3 Mean fasting plasma glucose (mmol/l) 10.4 10.9 10.3 10.5 SD 2.5 2.3 2.3 2.4 - Table 2—
Effects of therapeutic regimes
Placebo Nateglinide 120 mg Troglitazone 600 mg Nateglinide 120 mg and Troglitazone 600 mg Lipid parameters* Total cholesterol + 0.05 − 0.03 + 0.35 + 0.30 LDL cholesterol − 0.05 − 0.01 + 0.19 + 0.17 HDL cholesterol + 0.02 + 0.02 + 0.12 + 0.11 Triglycerides + 0.12 − 0.2 − 0.37 − 0.29 Weight* − 0.23 + 0.53 + 0.50 + 2.31 Number discontinued 0 0 1 0 Suggestive hypoglycemia 7 24 18 49 Percent of total 4.7 16 11.9 32.7 Confirmed hypoglycemia 3 1 2 10 Percent of total 2.0 0.7 1.3 6.7 Changes in liver enzymes 2 1 8 7 Number discontinued 2 0 7 4 Hematocrit >20% decrease 0 1.3 2.0 0 - *
↵* Adjusted mean changes from baseline.
- *
In this Issue
September 2002, 25(9)
Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes
